Drug combination therapy increases successful drug repositioning

Drug Discovery Today

Volumn 21, Issue 7, 2016, Pages 1189-1195

  Sun, Wei ^a   Sanderson, Philip E ^a   Zheng, Wei ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; AVIBACTAM PLUS CEFTAZIDIME; BACLOFEN; BIGUANIDE; CRIZOTINIB; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ITRACONAZOLE; MERCAPTOPURINE; METFORMIN; MILTEFOSINE; NALTREXONE; PAROXETINE; PHOSPHOTRANSFERASE INHIBITOR; PREDNISONE; RETIGABINE; SARACATINIB; SILDENAFIL; SORBITOL; TAMOXIFEN; TEMOZOLOMIDE; VINBLASTINE;

DRUG APPROVAL; DRUG COMBINATION; DRUG REPOSITIONING; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; IC50; POLYPHARMACOLOGY; REVIEW; ANIMAL; COMBINATION DRUG THERAPY; DRUG INTERACTION;

ANIMALS; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG REPOSITIONING; DRUG THERAPY, COMBINATION; HUMANS; POLYPHARMACOLOGY;

EID: 84971672804     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.05.015     Document Type: Review

References (67)

1. A. Mullard 2014 FDA drug approvals Nat. Rev. Drug Discov. 14 2015 77 81
2. C.W. Lindsley 2014 prescription medications in the United States: tremendous growth, specialty/orphan drug expansion, and dispensed prescriptions continue to increase ACS Chem. Neurosci. 6 2015 811 812
3. M. Boolell, and et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction Int. J. Impot. Res. 8 1996 47 52
4. C.R. Chong, and et al. Inhibition of angiogenesis by the antifungal drug itraconazole ACS Chem. Biol. 2 2007 263 270
5. C.M. Rudin, and et al. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer J. Thorac. Oncol. 8 2013 619 623
6. H.B. Nygaard, and et al. A Phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease Alzheimers Res. Ther. 7 2015 35
7. A.C. Kaufman, and et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice Annal. Neurol. 77 2015 953 971
8. A.L. Gray, and et al. Essential medicines are still essential Lancet 386 2015 1601 1603
9. W. Zheng, and et al. Phenotypic screens as a renewed approach for drug discovery Drug Discov. Today 18 2013 1067 1073
10. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
11. A.M. Sandercock, and et al. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling Mol. Cancer 14 2015 147
12. W. Sun, and et al. Chemical signatures and new drug targets for gametocytocidal drug development Sci. Rep. 4 2014 3743
13. S.A. Titus, and et al. High-throughput multiplexed quantitation of protein aggregation and cytotoxicity in a Huntington's disease model Curr. Chem. Genom. 6 2012 79 86
14. A.D. Ebert, and C.N. Svendsen Human stem cells and drug screening: opportunities and challenges Nat. Rev. Drug Discov. 9 2010 367 372
15. C. Carlson, and et al. Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy J. Biomol. Screen. 18 2013 1203 1211
16. B.J. Wainger, and et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons Cell Rep. 7 2014 1 11
17. J. Yuan, and et al. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets Science 333 2011 724 729
18. J. Mu, and et al. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs Nat. Genet. 42 2010 268 271
19. M. Shen, and et al. Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs PLoS One 8 2013 e75252
20. M. Xu, and et al. delta-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders J. Biol. Chem. 287 2012 39349 39360
21. J. Kouznetsova, and et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs Emerg. Microbes Infect. 3 2014 e84
22. J.J. Palop, and et al. A network dysfunction perspective on neurodegenerative diseases Nature 443 2006 768 773
23. A.L. Barabasi, and et al. Network medicine: a network-based approach to human disease Nat. Rev. Genet. 12 2011 56 68
24. M.L. Bolognesi Polypharmacology in a single drug: multitarget drugs Curr. Med. Chem. 20 2013 1639 1645
25. G. Rastelli, and L. Pinzi Computational polypharmacology comes of age Front. Pharmacol. 6 2015 157
26. A. Valencia, and et al. A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities Toxicol. Appl. Pharmacol. 273 2013 427 434
27. J. Lamb, and et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease Science 313 2006 1929 1935
28. B. Chen, and et al. Relating chemical structure to cellular response: an integrative analysis of gene expression, bioactivity, and structural data across 11,000 compounds CPT Pharmacometrics Syst. Pharmacol. 4 2015 576 584
29. M. Reutlinger, and et al. Multi-objective molecular de novo design by adaptive fragment prioritization Angewandte Chemie 53 2014 4244 4248
30. T. Rodrigues, and et al. Multidimensional de novo design reveals 5-HT2B receptor-selective ligands Angew. Chem. 54 2015 1551 1555
31. T.S. Gujral, and et al. Exploiting polypharmacology for drug target deconvolution Proc. Natl. Acad. Sci. U. S. A. 111 2014 5048 5053
32. P.W. Rose, and et al. The RCSB Protein Data Bank: views of structural biology for basic and applied research and education Nucleic Acids Res. 43 2015 D345 D356
33. S. de Bie, and et al. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study Br. J. Clin. Pharmacol. 80 2015 304 314
34. R.M. Webster Combination therapies in oncology Nat. Rev. Drug Discov. 15 2016 81 82
35. J. Jia, and et al. Mechanisms of drug combinations: interaction and network perspectives Nat. Rev. Drug Discov. 8 2009 111 128
36. Z.A. Knight, and et al. Targeting the cancer kinome through polypharmacology Nat. Rev. Cancer 10 2010 130 137
37. A.I. Daud, and et al. Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors Clin. Cancer Res. 18 2012 1092 1100
38. Z. Yu, and et al. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo Oncotarget 6 2015 32930 32943
39. A.S. Crystal, and et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer Science 346 2014 1480 1486
40. D.D. Ho Time to hit HIV, early and hard N. Eng. J. Med. 333 1995 450 451
41. M. Abramowicz, and et al. A 4-drug combination (Viekira Pak) for hepatitis C JAMA 313 2015 1857 1858
42. E.A. Ashley, and et al. Spread of artemisinin resistance in Plasmodium falciparum malaria N. Eng. J. Med. 371 2014 411 423
43. B.T. Mott, and et al. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations Sci. Rep. 5 2015 13891
44. J.D. Planer, and et al. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi PLoS Negl. Trop. Dis. 8 2014 e2977
45. Z.A. Polat, and et al. Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis Clin. Experiment. Ophthalmol. 42 2014 151 158
46. E. Matsuki, and et al. Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy Int. Med. 50 2011 909 914
47. S. Attarian, and et al. An exploratory randomised double-blind and placebo-controlled Phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A Orphanet J. Rare Dis. 9 2014 199
48. M.D. Zilberberg, and et al. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study Crit. Care 18 2014 596
49. G.G. Zhanel, and et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination Drugs 73 2013 159 177
50. Y. Jin, and et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J. Natl. Cancer Inst. 97 2005 30 39
51. C.M. Kelly, and et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ 340 2010 c693
52. J.J. Kiser, and et al. Drug-drug interactions during antiviral therapy for chronic hepatitis C Nat. Rev. Gastroenterol. Hepatol. 10 2013 596 606
53. S. Ciesek, and et al. Second-wave protease inhibitors: choosing an heir Clin. Liver Dis. 15 2011 597 609
54. P. Csermely, and et al. The efficiency of multi-target drugs: the network approach might help drug design Trends Pharmacol. Sci. 26 2005 178 182
55. S. Frantz The trouble with making combination drugs Nat. Rev. Drug Discov. 5 2006 881 882
56. G.X. Jin, and S.T.C. Wong Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines Drug Discov. Today 19 2014 637 644
57. P. Nowak-Sliwinska, and et al. Optimization of drug combinations using feedback system control Nat. Protocols 11 2016 302 315
58. F. Barneh, and et al. Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database Brief. Bioinf. 2015 pii: bbv094
59. J.D. Duke, and et al. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions PLoS Comput. Biol. 8 2012 e1002614
60. Y. Lu, and et al. A novel algorithm for analyzing drug-drug interactions from MEDLINE literature Sci. Rep. 5 2015 17357
61. S. Vilar, and et al. Similarity-based modeling in large-scale prediction of drug-drug interactions Nat. Protocols 9 2014 2147 2163
62. E. Lounkine, and et al. Large-scale prediction and testing of drug activity on side-effect targets Nature 486 2012 361 367
63. M. Markowitz, and et al. A randomized open-label study of 3-versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals JAIDS 66 2014 140 147
64. C.R. Chong, and et al. A clinical drug library screen identifies astemizole as an antimalarial agent Nat. Chem. Biol. 2 2006 415 416
65. R. Huang, and et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Sci. Transl. Med. 3 2011 80ps16
66. T.I. Oprea, and et al. Lead-like, drug-like or Pub-like: how different are they? J. Comput. Aided Mol. Des. 21 2007 113 119
67. J. Wang, and et al. Reversal of a full-length mutant Huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation BMC Neurosci. 6 2005 1